FR2857595B1 - Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie - Google Patents

Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie

Info

Publication number
FR2857595B1
FR2857595B1 FR0308800A FR0308800A FR2857595B1 FR 2857595 B1 FR2857595 B1 FR 2857595B1 FR 0308800 A FR0308800 A FR 0308800A FR 0308800 A FR0308800 A FR 0308800A FR 2857595 B1 FR2857595 B1 FR 2857595B1
Authority
FR
France
Prior art keywords
agony
medicament
treating
preparing
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0308800A
Other languages
English (en)
Other versions
FR2857595A1 (fr
Inventor
De Lassauniere Pierre Chabrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to FR0308800A priority Critical patent/FR2857595B1/fr
Priority to EP04767694A priority patent/EP1648480A2/fr
Priority to US10/564,825 priority patent/US20070082013A1/en
Priority to PCT/FR2004/001870 priority patent/WO2005009450A2/fr
Publication of FR2857595A1 publication Critical patent/FR2857595A1/fr
Application granted granted Critical
Publication of FR2857595B1 publication Critical patent/FR2857595B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0308800A 2003-07-18 2003-07-18 Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie Expired - Fee Related FR2857595B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR0308800A FR2857595B1 (fr) 2003-07-18 2003-07-18 Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie
EP04767694A EP1648480A2 (fr) 2003-07-18 2004-07-16 Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter la detresse pulmonaire en phase terminale
US10/564,825 US20070082013A1 (en) 2003-07-18 2004-07-16 Use of botulinum toxin for producing drug for preventing or treating final phase of lung troubles
PCT/FR2004/001870 WO2005009450A2 (fr) 2003-07-18 2004-07-16 Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter la detresse pulmonaire en phase terminale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0308800A FR2857595B1 (fr) 2003-07-18 2003-07-18 Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie

Publications (2)

Publication Number Publication Date
FR2857595A1 FR2857595A1 (fr) 2005-01-21
FR2857595B1 true FR2857595B1 (fr) 2005-10-07

Family

ID=33548253

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0308800A Expired - Fee Related FR2857595B1 (fr) 2003-07-18 2003-07-18 Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie

Country Status (4)

Country Link
US (1) US20070082013A1 (fr)
EP (1) EP1648480A2 (fr)
FR (1) FR2857595B1 (fr)
WO (1) WO2005009450A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1488803B1 (fr) * 1993-12-28 2008-03-26 Allergan, Inc. Composante neurotoxique de la toxine botulinique pour la traitement de la dystonie cervicale
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases

Also Published As

Publication number Publication date
FR2857595A1 (fr) 2005-01-21
EP1648480A2 (fr) 2006-04-26
WO2005009450A2 (fr) 2005-02-03
WO2005009450A3 (fr) 2005-09-15
US20070082013A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
EP1759710A4 (fr) Remède ou médicament préventif pour l'arthrite
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
EP1583750A4 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
BR0014890B1 (pt) sistema para alinhar dados de tratamento e/ou diagnàstico refrativo.
MA25820A1 (fr) Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete.
EP1679962A4 (fr) Seves moleculaires de zeolite pour l'elimination des toxines
FR2808205B1 (fr) Cloison de separation pour dispositif implantable d'injection
EP1604664A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
MA26779A1 (fr) Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.
EP1655037A4 (fr) Agent visant a faire baisser le cholesterol serique ou agent de prevention ou therapeutique pour l'atherosclerose
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
EP1687790A4 (fr) Systeme d'education interactif pour enseigner des soins aux patients
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EP1815387A4 (fr) Systeme de verification d'identite dote de dispositifs d'entree interoperables et interchangeables
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
FR2810905B1 (fr) Additif pour minimiser les phenomenes d'adsorption et/ou d'electroosmose
FR2858072B1 (fr) Peripherique d'entree pour ordinateur ou similaire
EP1537875A4 (fr) Medicament preventif/curatif pour l'arteriosclerose
EP1546377A4 (fr) Methodes et compositions de traitement de la douleur et des troubles douloureux a l'aide des molecules 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002,16209, 314, 636, 27410, 33260, 619,15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 ou 13424
FR2817727B1 (fr) Ecran de douche pour receveur de douche ou baignoire
FR2773717B1 (fr) Catheter pour canal corporel
FR2788301B1 (fr) Sas d'isolement pour des personnes ou des vehicules
EP1726313A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
FR2889067B1 (fr) "utilisation d'une fraction proteique laitiere pour preparer une composition amincissante et/ou ameliorant la composition corporelle"

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100331